Immunoglobulin heavy chain variable ( IGHV) testing has become an important prognostic and therapeutic factor in chronic ...

A two-time breast cancer survivor who was diagnosed with chronic lymphocytic leukemia in 2020 discussed her belief in the power of minimal residual disease testing. Two-time breast cancer survivor Sue ...

About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

In vitro studies have suggested that BTKi therapy can suppress NOTCH1 activation via B-cell receptor–NOTCH1 interactions, providing a mechanistic rationale for these clinical results.

Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL). Association of relapse of FLT3-ITD AML ...

(WASHINGTON, June 21, 2024) – Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs) who received frequent tests for immunoglobulin G (IgG) were less likely to experience ...

NORTH CHICAGO, Ill., Dec. 6, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), today announced results from a long-term integrated analysis of two Phase 3 clinical studies and additional pooled analysis ...

The data also show how the economic burden of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is increasing. New data suggest patients who receive a diagnosis of chronic lymphocytic ...

In fact, of those patients, about 10% of CLL/SLL patients have the high-risk del (17p) and/or TP53 mutation before starting treatment, and about 40% of patients will develop del (17p) and/or TP53 ...